Pfizer, Inc. · NYSE:PFE

Pfizer — Goldman Sachs Global Healthcare Conference 2008

22 slides from Pfizer's conference presentation, Jun 11, 2008

  1. Slide 1: Goldman Sachs Global Healthcare Conference

    Goldman Sachs Global Healthcare Conference Martin Mackay President, Global Research & Development June 11, 2008

  2. Slide 2: Forward-Looking Statements And Non-GAAP Financial Information

    Forward-Looking Statements And Non-GAAP Financial Information „ Discussions at this meeting will include forward-looking statements. Actual results could differ materially from those projected in the forward-looking statements. The factors that could cause actual results to differ are discussed in P

  3. Slide 3: Our Path Forward

    Our Path Forward Maximize Revenues from Existing, New and Diverse Sources „ Take Advantage of Size, Scale of Pfizer Establish a Lower, More „ Operate with Agility, Flexible Cost Base Speed, Focus of an Entrepreneurial Organization Innovate Our Business Model Drive Greater Total Shareholder Return

  4. Slide 4: Our Path Forward: Strategies For Growth

    Our Path Forward: Strategies For Growth US Lipitor Post Today LOE Lipitor Optimize the Patent-Protected Portfolio „ Maximize the Value of New and Inline Products „ Advance Compounds in the Pipeline Maximize Revenues Capitalize on Established Products Sustainable TSR Growth Grow in Emerging Markets „

  5. Slide 5: Optimizing The Patent Protected Portfolio

    Optimizing The Patent Protected Portfolio Pipeline as of Feb 28, 2008 Approved More than Selzentry 300 Phase 1 Phase 2 Phase 3 In Reg. Lyrica for Discovery 47 37 16 2 Fibromyalgia Projects fesoterodine (EU) „ Accelerating Pipeline with sharpened focus on key disease areas „ Strong flow of medicines

  6. Slide 6: Aggressive Goal To Rebuild Our Phase 3 Portfolio

    Aggressive Goal To Rebuild Our Phase 3 Portfolio „ Total of 15–20 Phase 3 starts 2008–2009 „ Phase 3 total programs grow to 24–28 by December 2009 „ 15–20 regulatory submissions between 2010–2012

  7. Slide 7: Today's Phase 3 Portfolio

    Today’s Phase 3 Portfolio „ axitinib – Pancreatic Cancer „ PD-332334 – GAD „ apixaban – VTE Prevention „ S,S-reboxetine – Fibromyalgia NMEs „ CP-945598 – Obesity „ Zithromax/chloroquine – Malaria „ CP-751871 - Lung Cancer „ PF-1228305 (Thelin) – PAH New „ apixaban – Indications Atrial Fibrillation „

  8. Slide 8: Projected 15–20 Phase 3 Starts 2008–2009

    Projected 15–20 Phase 3 Starts 2008–2009 9 CP-751871 „ PF-885706 – GERD „ PF-868554 „ PF-734200 – Lung Cancer – HCV – Diabetes „ PF-299804 – Cancer „ PF-4383119 „ PF-4194471 „ PF-4522625 – OA Pain „ PH-797804 – RA – HIV – Seasonal Flu NMEs „ PD-200390 „ IV sulopenem/Oral „ CP-690550 „ UK-453061 – In

  9. Slide 9: Pfizer Disease Area Priorities

    Pfizer Disease Area Priorities Invest to Win First or High Market High Best in Class Growth Unmet Need 9 9 9 „ Oncology „ Pain „ Immunology/Inflammation „ Diabetes/Obesity „ Alzheimer’s Disease „ Schizophrenia

  10. Slide 10: Recent Oncology Phase 3 Starts

    Recent Oncology Phase 3 Starts Phase 3 Starts Since ASCO 2007 Sutent First line CRC Sutent Second line NSCLC Sutent Adjuvant RCC Axitinib Pancreatic cancer CP-751871 First line NSCLC CP-751871 Refractory NSCLC Phase 3 Trials Expected to be Initiated in 2008 Sutent First line HCC Sutent Second line m

  11. Slide 11: Potential New Indications Expected To Drive Value

    Potential New Indications Expected To Drive Value Colorectal es nu ve Non Small Cell Lung Re Hepatocellular Carcinoma Breast Renal Cell Carcinoma & Gastrointestinal Stromal Tumor Time

  12. Slide 12: Pfizer Oncology Clinical Portfolio

    Pfizer Oncology Clinical Portfolio TSP-1 (CVX-045)* Platform Key Ang-2 Ant Anti-Angiogenesis (CVX-060)* Transitions Since ASCO 2007 Signal Transduction ALK1 mAb (PF-3446962) Immunotherapy sVEGFR (PF-337,210) Cytotoxic/ mRTK Potentiators P-Cad mAb (SU-14,813) (PF-3, 732,010) Pan-ErbB FAK Sutent® (PF-

  13. Slide 13: Axitinib Phase 3 in 1st Line NSCLC

    Axitinib Phase 3 First or Best in Class High Market Growth High Unmet Need In 1st Line NSCLC 9 9 9 „ Axitinib demonstrates activity as a single-agent in refractory NSCLC patients (14.6 months median survival) „ Axitinib demonstrates good combinability with chemotherapy Overall Survival Phase 3 Study

  14. Slide 14: CP-751871: Phase 2 NSCLC Activity

    CP-751871: First or Best in Class High Market Growth High Unmet Need Phase 2 NSCLC Activity 9 9 9 Treatment-naïve Stage IIIB/IV Carboplatin/Paclitaxel NSCLC Patients Carboplatin/Paclitaxel + CP-751,871 Overall Population Dose (mg/kg) 0 10 20 100 Sample size (n) 50 46 53 Dose: 80 0 Median PFS (months

  15. Slide 15: Recent Oncology Licensing And Acquisitions

    Recent Oncology Licensing And Acquisitions Company/Compound Value to Pfizer Portfolio Avant – license Novel vaccine in Phase 2b/3 for GBM CDX-110 (EGFRvIII vaccine) High unmet medical need Serenex – acquisition Phase I, novel mechanism SNX-5422 (Hsp90 inhibitor) Complementary to portfolio CovX – acq

  16. Slide 16: CP-690550: JAK-3 Inhibitor

    First or High Market High Unmet CP-690550: Best in Class Growth Need JAK-3 Inhibitor 9 9 9 RA Phase 2a Response Rate 100 80 60 40 20 0 0 2 4 6 Weeks Placebo 5 mg 15 mg 30 mg Phase 2b dose ranging in rheumatoid arthritis ongoing – anticipate Kremer JM et al, ACR 2006 presentation at ACR 2008 Simultan

  17. Slide 17: PF-4383119 (RN-624): Nerve Growth Factor Inhibitor

    PF-4383119 (RN-624): First or Best in Class High Market Growth High Unmet Need Nerve Growth Factor Inhibitor 9 9 9 Heavy Chain Projected 1st Biotherapeutic for Pain „ Blocks Nerve Growth Factor (NGF) NGF Š Humanized monoclonal antibody „ Efficacy demonstrated in Phase 2 osteoarthritis (OA) pain stud

  18. Slide 18: PF-4383119: Osteoarthritis Knee Pain

    PF-4383119: Osteoarthritis Knee Pain Single IV Infusion: Mean Change from Baseline (mm) Over 8 Weeks Panel 1 Panel 2 Baseline Pain = 43–46 mm Baseline Pain = 54–60 mm n=12 n=6 n=6 n=6 n=26 n=27 n=26 0 -5 -10 -15 -20 -25 * -30 * * -35 * Placebo 0.1 mg/kg 0.3 mg/kg 1.0 mg/kg Encouraging Phase 1/2 Effi

  19. Slide 19: Biotherapeutics In The Pipeline

    86 Biotherapeutics In The Pipeline Research Development Marketed 60 26 5 $1.4 B 2007 Diverse Portfolio Revenues 8 TAs (interferon beta-1a) (dalteparin sodium injection) 6 Modalities 53 MAbs 8 Vaccines (pegvisomant for injection)

  20. Slide 20: Rebuilding The Phase 3 Portfolio

    Rebuilding The Phase 3 Portfolio Number of Phase 3 Programs 24–28 22–24 16 Mar '08 Mar '09 Dec '09 Projected Projected NMEs New Indications

  21. Slide 21: Building Momentum

    Building Momentum Sutent, Champix, Approved for GIST and RCC, Smoking Cessation, PAH (Japan) sildenafil Zithromac SR, Xalacom, Submitted for Bacterial Infections, Glaucoma, HIV Treatment Maraviroc Experienced Patients (Japan) Lyrica, Fablyn Submitted for Fibromyalgia, Osteoporosis Treatment (Europe)

  22. Slide 22: Goldman Sachs Global Healthcare Conference

    Goldman Sachs Global Healthcare Conference Martin Mackay President, Global Research & Development June 11, 2008

Pfizer — Goldman Sachs Global Healthcare Conference 2008 on 6ix